ADVANCING DIGITAL THERAPEUTICS:

TRANSFORMING THE FUTURE OF EVIDENCE-BASED CARE

Ramandeep Kaur, PhD - Associate Research Scientist

Introduction

Digital health encompasses a broad array of technologies, such as electronic health records (EHRs), telehealth platforms, wearables, and mobile apps, that leverage software, connectivity, and data to enhance health outcomes.[1] Within this expanding ecosystem, Digital Therapeutics (DTx) represent a distinct, evidence-based category of interventions that use software to prevent, manage, or treat medical conditions.[2] DTx have gained significant traction in response to rising demand for value-based, patient-centered care. They are increasingly integrated into treatment pathways for conditions such as mental health disorders, diabetes, attention deficit hyperactivity disorder (ADHD), and substance use disorders. However, despite their promise, DTx face several challenges - including evolving regulatory landscapes, inconsistent reimbursement models, and integration barriers within traditional healthcare systems.[3,4]

The Digital Therapeutics Alliance (DTA), founded in 2017, plays a pivotal role in shaping the global DTx landscape. As a non-profit consortium of industry leaders, developers, payors, clinicians, and policymakers, DTA advocates for standards, policy alignment, and clinical rigor to support the safe, effective, and routine use of DTx in healthcare.[5] According to DTA, DTx are software-driven, evidence-based interventions intended to prevent, manage, or treat a medical disorder or disease. Unlike general wellness or lifestyle apps, DTx must demonstrate clinical effectiveness, meet regulatory standards, and be integrated into clinical care - either as standalone treatments or alongside conventional therapies. DTA further positions DTx as the highest-impact category within digital health, distinct from less-regulated tools such as wellness apps, patient monitoring systems, or digital diagnostics.[6]

From a regulatory standpoint, DTx are treated as Software as a Medical Device (SaMD). In the United States (US), the Food and Drug Administration (FDA) oversees DTx under this framework, while in Europe, the European Medicines Agency (EMA) regulates DTx under the Medical Device Regulation (MDR). Navigating these frameworks is critical to unlocking the full potential of DTx.

This article offers a comprehensive exploration of the dynamic DTx landscape - unpacking the regulatory frameworks, reimbursement pathways, and approval challenges that shape their development and deployment. It also examines the future trajectory of this transformative category, providing actionable insights for stakeholders across healthcare, technology, and policy sectors who are navigating the shift toward software-driven, evidence-based care.

Key Guidance Documents

As DTx gains momentum as evidence-based treatments, various regulatory and industry frameworks have emerged to guide their safe, effective, and ethical development. These documents (summarized in **Table 1** below) support developers in clinical evaluation, risk management, and data protection, helping build trust and enabling integration into global healthcare systems.

Table 1: Essential guidance documents and frameworks utilized for DTx

Source	Standard/ Guidance document	Key Focus Areas
Digital Therapeutics Alliance (DTA)	Guidance to Industry: Classification of Digital Health Technologies (2023)[6]	Differentiates DTx from wellness/ diagnostic tools; outlines clinical and regulatory expectations
	DTx Product Best Practices (2021)[7]	Core principles for safety, clinical integrity, and user-centered design
	European best-practice guide (2022)[8]	Guidance on reimbursement, interoperability, data security, and usability
FDA	SaMD: Clinical Evaluation (2017)[9]	Clinical evidence standards for software-based interventions
	Digital Health Technologies for Remote Data Acquisition in Clinical Investigations (2023)[10]	Use of digital tools for remote trial data collection
	Cybersecurity in Medical Devices: Quality System Consideration (2022)[11]	Cybersecurity requirements for device design and FDA submissions
EU/IMDRF	EU MDR[12] & IVDR[13]	Medical device classification, conformity, and post-market surveillance for DTx
	IMDRF/SaMD guidance[14]	International framework for SaMD classification and regulation
ISO / ITU-T	ISO 14971:2019[15]	Risk management for medical devices, fully applicable to DTx
	ITU-T H.810 (Continua Design Guidelines)[16]	Interoperability standards for digital health systems
Cybersecurity & Ethics	Industry consensus on secure data-handling (2018)[17]	Data protection, GDPR compliance, and ethical data use in DTx

DTx: Digital therapeutics; EU: European Union; FDA: Food and Drug Administration; GDPR: General Data Protection Regulation; IMDRF: International Medical Device Regulators Forum; ISO: International Standard Organization; ITU-T: International Telecommunication Union – Telecommunication Standardization Sector; IVDR: In Vitro Diagnostic Regulation; MDR: Medical Device Regulation; SaMD: Software as a Medical Device

These frameworks not only support regulatory compliance but also help accelerate clinical adoption and payer confidence.

Regulatory Approval Pathways

Given the unique nature of software-based interventions, regulatory bodies have established specialized pathways to evaluate and authorize DTx products. These regulatory pathways vary by region (US and EU) but generally follow a structured process to ensure safety, efficacy, and quality, as summarized in **Table 2** below for US and Europe requirements.

Table 2: Regulatory requirements for DTx approval in the US and Europe

Regulatory Component	United States (FDA)	Europe (EU – MDR/IVDR)
Regulatory Framework	Software as a Medical Device (SaMD) under FDA[9]	MDR (2017/745)[12] or IVDR for diagnostics[13]
Device Classification	Class II (moderate risk) or Class III (high risk)	Class I (low), IIa/IIb (moderate), III (high risk) depending on use and impact
Approval Pathways	- 510(k): Substantial equivalence - De Novo: Novel, low/moderate risk - PMA: High-risk devices (rare for DTx) - Pre-Cert Program (pilot, paused)	CE Mark via Notified Body (for Class IIa and above) following conformity assessment
Clinical Evidence	Required to demonstrate safety and efficacy via trials or real-world data	Robust clinical evidence (literature, real-world data, or clinical investigation) required to prove safety and benefit
Quality Management	Must comply with 21 CFR Part 820 (Quality System Regulation)	ISO 13485 or equivalent QMS required for design, manufacturing, and post-market processes
Labeling Requirements	Clear instructions and labeling mandatory	Accurate, comprehensive labeling aligned with intended use and safety
Cybersecurity & Data Privacy	Must address software reliability, cybersecurity, and HIPAA compliance	Cybersecurity per MDR guidance; data protection under GDPR,18 including user consent
Post-Market Surveillance	Required- AE reporting and ongoing performance monitoring	Mandatory; AE reporting

AE: Adverse event; DTx: Digital therapeutics; FDA: Food and Drug Administration; GDPR: General Data Protection Regulation; HIPAA: Health Insurance Portability and Accountability Act; ISO: International Standard Organization; IVDR: In Vitro Diagnostic Regulation; MDR: Medical Device Regulation; PMA: Pre-market Approval; QMS: Quality Management System; SaMD: Software as a Medical Device

Reimbursement Strategies

Following regulatory approval, achieving reimbursement is a key milestone for market success and patient access, requiring evidence of clinical value, cost-effectiveness, and alignment with payer priorities. **Table 3** presents the reimbursement requirements for DTx across the US and Europe. In the US, reimbursement remains fragmented without a standardized pathway, though emerging strategies and regulatory efforts are improving access. In Europe, reimbursement varies by country through the Health Technology Assessment (HTA) agencies, as each nation manages its own healthcare and coverage decisions independently of the EU.

Table 3: Reimbursement requirements for DTx across US and Europe

Reimbursement Requirements	United States	Europe
Regulatory Prerequisite	FDA clearance/authorization (510(k), PMA, De Novo) as SaMD	CE mark under Medical Device Regulation (MDR)[12]
Reimbursement Decision Maker	Medicare (CMS),[19] Medicaid (state-level), commercial insurers, employers	National-level processes; varies by country
Coverage Framework	No unified pathway; variable by payer type	National-level processes; varies by country
Public Payers	• Medicare: limited; some coverage via RTM codes and value-based models • Medicaid: varies by state	• Germany: DiGA fast-track[20] • France: PECAN pathway[21] • Belgium: mHealthBelgium (M3)[22] • Nordics/UK: HTA-driven
Private Payers / Commercial Insurers	May reimburse via medical/pharmacy benefit or direct/value-based contracts	Varies widely; conditional coverage based on HTA, CE mark, and cost-effectiveness
Special Billing Codes	RTM CPT codes: 98975, 98976/77, 98980/81[23]	Country-specific codes; DiGA and PECAN offer early listing with provisional codes
Pharmacy Pathway	National Drug Code allows inclusion in drug formularies (pharmacy benefit)	Less common; DTx often considered under medical device reimbursement routes
Employer / DTC Options	Employers offer DTx via wellness programs	Less common; DTx often considered under medical device reimbursement routes
	DTC subscriptions bypass traditional payers	
Evidence Requirements	RCTs, real-world data, economic models (ROI, cost-effectiveness), engagement metrics	Clinical evidence, real-world data, cost-effectiveness/budget impact analyses
Integration into Care	DTx must demonstrate fit into clinical workflows; RTM supports clinical use	Required to show alignment with standard care and value to clinicians

CMS: Centers for Medicare & Medicaid Services; CPT: Current Procedural Terminology; DiGA: Digital Health Applications; DTC: Direct to consumer; DTx: Digital therapeutics; FDA: Food and Drug Administration; HTA: Health Technology Assessment; MDR: Medical Device Regulation; PMA: Pre-market Approval; RCT: Randomized controlled trial; ROI: Return On Investment; RTM: Remote Therapeutic Monitoring; SaMD: Software as a Medical Device

Case Studies

Table 4 presents selected digital therapeutics that have successfully achieved regulatory approval and reimbursement, highlighting their clinical and commercial impact.[24]

Table 4: Successful approved and reimbursed digital therapeutics

DTx (Developer)	Indication	Regulatory Status (Year)	Reimbursement	Health Impact (Evidence type)
reSET® and reSET-O® (Pear Therapeutics, US)[25]	Substance use disorder and opioid use disorder	De Novo FDA clearance (reSET®- 2017 and reSET-O®- 2018)	State Medicaid programs; private insurers	Improved abstinence rates and treatment retention (RCT)
Sleepio (Big Health, UK/US)[26]	Chronic insomnia	CE marked- EU; FDA enforcement discretion- US (2022 - UK)	NHS (UK); US employer programs	Reduced primary care visits and prescription sleep aid use (RCT + RWE)
Kaia Health (Germany/US)[27]	Chronic back pain and COPD	CE marked- EU (Chronic back pain- 2018, COPD- 2021)	Full statutory insurance reimbursement (Germany)	Reduced pain scores; improved physical function (RCT + RWE)
Deprexis (GAIA AG, Germany)[28]	Depression	CE marked- EU (2020 Germany)	Approved under DiGA Fast Track (Germany)	Demonstrated efficacy (RCT)

COPD: Chronic Obstructive Pulmonary Disorder; DiGA: Digital Health Applications; EU: European union; FDA: Dood and Drug Administration; NHS: National Health Service; RCTs: Randomized controlled trials; UK: United Kingdom; US: United States

Challenges & Future Directions

Despite their potential, DTx faces several hurdles:

1. **Regulatory Complexity:** Varying regional standards (e.g., FDA, MDR, DiGA) create barriers to global market access. Many DTx are still regulated under general medical device rules that don't fully address software-specific needs.[29,30]
2. **Reimbursement Gaps:** Inconsistent and fragmented reimbursement systems limit access. Payers often lack clear frameworks to assess the clinical and economic value of DTx.[31]
3. **Evidence Generation:** Demonstrating efficacy through RCTs or real-world data is costly and time-consuming; particularly challenging for early-stage DTx developers.
4. **Clinical Integration:** Adoption is hindered by workflow disruptions and limited clinician awareness or training in prescribing DTx.[32]
5. **Data Privacy & Security:** Compliance with laws like GDPR and HIPAA is complex, and safeguarding cloud-based platforms requires stringent protection.
6. **Patient Engagement:** Sustaining user engagement is difficult, especially among populations with limited digital access or connectivity.

Despite these hurdles, momentum continues to build for DTx as healthcare systems seek more scalable and personalized solutions. Expanding reimbursement through fast-track models like Germany's DiGA and France's PECAN, and a shift to outcome-based payments promise broader access. Regulatory clarity is improving with dedicated frameworks from the FDA and efforts toward global harmonization. Adoption will accelerate through better EHR integration, provider education, and AI- and wearable-driven personalization. DTx use is growing beyond mental health and diabetes into areas like oncology and cardiovascular care, while hybrid models that combine digital and human support are becoming standard in chronic and preventive care.

Conclusion

Digital therapeutics represent a clinically validated and regulated category within the broader digital health ecosystem, offering software-based interventions to treat or manage medical conditions. As regulatory bodies across the US, EU, and other regions establish clearer pathways for approval, and reimbursement models gradually evolve, DTx continue to gain credibility and adoption. However, challenges remain, particularly around regulatory harmonization, real-world evidence generation, and integration into healthcare systems. With advancing technology and growing demand for personalized, scalable care, DTx are poised to play an increasingly central role in the future of evidence-based medicine. To fully realize this potential, cross-sector collaboration will be essential - bringing together regulators, payors, clinicians, technology developers, academic researchers, and patient advocacy groups to align on standards, enable evidence generation, streamline integration into clinical workflows, and ensure equitable access across populations as the digital therapeutics landscape continues to evolve.

References

1. McKinsey & Company. (2021) The future of digital health: Opportunities and challenges. https://www.mckinsey.com/industries/life-sciences/our-insights/the-health-benefits-and-business-potential-of-digital-therapeutics. Accessed 16 July, 2025
2. Wang C, Lee C, Shin H. (2023) Digital therapeutics from bench to bedside. NPJ Digit Med. Mar 10;6(1):38.
3. Ferrante M, Esposito LE, Stoeckel LE. (2024) From palm to practice: prescription digital therapeutics for mental and brain health at the National Institutes of Health. Front Psychiatry. Sep 10;15:1433438.
4. Miao BY, Arneson D, Wang M, Butte AJ. (2022) Open challenges in developing digital therapeutics in the United States. PLOS Digit Health 1(1): e0000008.
5. Lederman R, D'Alfonso S. (2021) The Digital Therapeutic Alliance: Prospects and Considerations. JMIR Ment Health. 20;8(7):e31385.
6. Digital Therapeutics Alliance (DTA). (2023). Guidance to Industry: Classification of Digital Health Technologies.
7. Digital Therapeutics Alliance (DTA). (2021). Digital Therapeutics (DTx) Product Best Practices.
8. Digital Therapeutics Alliance (DTA). (2022). DTx Value Assessment & Integration Guide.
9. U.S. Food and Drug Administration (FDA). (2017). Software as a Medical Device (SaMD): Clinical Evaluation – Guidance for Industry and FDA Staff. International Medical Device Regulators Forum (IMDRF).
10. U.S. Food and Drug Administration (FDA). (2023). Digital Health Technologies for Remote Data Acquisition in Clinical Investigations – Guidance for Industry, Investigators, and Other Stakeholders.
11. U.S. Food and Drug Administration (FDA). (2022). Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions.
12. European Commission. (2017). Medical Device Regulation (EU) 2017/745.
13. Regulation (EU) 2017/746 of the European Parliament and of the Council of 5 April 2017 on in vitro diagnostic medical devices and repealing Directive 98/79/EC and Commission Decision 2010/227/EU.
14. International Medical Device Regulators Forum (IMDRF). (2014). Software as a Medical Device (SaMD): Possible Framework for Risk Categorization and Corresponding Considerations.
15. International Organization for Standardization (ISO). (2019). ISO 14971:2019 – Medical Devices – Application of Risk Management to Medical Devices.
16. 16."H.810: Interoperability design guidelines for personal connected health systems: Introduction". https://www.itu.int/rec/T-REC-H.810 Accessed 16 July, 2025
17. Schubert, K.D., Barrett, D. (2024). Data Governance, Privacy, and Ethics. In: Lacity, M.C., Coon, L. (eds) Human Privacy in Virtual and Physical Worlds. Technology, Work and Globalization. Palgrave Macmillan, Cham.
18. European Union. (2016). General Data Protection Regulation (GDPR) – Regulation (EU) 2016/679.
19. Centers for Medicare & Medicaid Services (CMS). Coverage and coding for digital health technologies. https://www.cms.gov/medicare/coding-billing/guide-medical-technology-companies-other-interested-parties Accessed 28 July, 2025
20. BfArM – Federal Institute for Drugs and Medical Devices. Directory of Digital Health Applications (DiGA). https://www.bfarm.de/EN/Medical-devices/Tasks/DiGA-and-DiPA/Digital-Health-Applications/_node.html Accessed 28 July, 2025
21. Haute Autorité de Santé (HAS). (n.d.). PECAN program https://gnius.esante.gouv.fr/fr/financements/fiches-remboursement/prise-en-charge-anticipee-numerique-pecanAccessed 28 July, 2025
22. mHealthBelgium. (2024) Validation pyramid for mobile health applications. https://mhealthbelgium.be/validation-pyramid Accessed 16 July, 2025
23. American Medical Association. (2022). Remote Therapeutic Monitoring (RTM) CPT codes overview.
24. Pushkarna et al. (2025) Collaborations Between Pharma and Digital Health Startups: Advancing Innovation and Reimbursement in Digital Health Technologies. ISPOR Montreal
25. Novartis (2918) Sandoz and Pear Therapeutics announce launch of reSET® for treatment of patients with Substance Use Disorder. https://www.novartis.com/news/media-releases/sandoz-and-pear-therapeutics-announce-launch-reset-treatment-patients-substance-use-disorder Accessed 16 July, 2025
26. Lovell T. (2022) Sleepio becomes first digital therapeutic to receive NICE guidance. https://www.mobihealthnews.com/news/emea/sleepio-becomes-first-digital-therapeutic-receive-nice-guidance Accessed 28 July, 2025
27. Kaia Health. (2023) Kaia Health Digital COPD Application Approved by Germany's "FDA". https://kaiahealth.com/newsroom/press-releases/kaia-health-digital-copd-application-approved-by-germanys-fda/ Accessed 28 July, 2025
28. Engberg A. (2021) Germany approves new digital mental health app for prescription. https://www.mobihealthnews.com/news/emea/germany-approves-new-digital-mental-health-app-prescription Accessed 28 July, 2025
29. Food and Drug Administration (FDA). (2019). Clinical decision support software: Guidance for industry and FDA staff.
30. Food and Drug Administration (FDA). (2023). Digital health policies and public health solutions.
31. Digital Therapeutics Alliance. (2023). Reimbursement models for DTx.
32. Digital Therapeutics Alliance (DTA). (2022) DTx Value Assessment & Integration Guide.